A Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) - Lung Cancer Mutation Consortium (LCMC3)

  • Non-Small Cell Lung Cancer
Trial Status:

Active, not recruiting

This trial runs in
  • Atlanta
  • Aurora
  • Boston
  • Columbus
  • Commack
  • Danvers
  • Detroit
  • Duarte
  • Harrison
  • Lebanon
  • middletown-township
  • Montvale
  • New Haven
  • New York
  • Santa Monica
  • St. Louis
  • Tampa
  • Uniondale
Trial Identifier:

NCT02927301 ML39236

      Show trial locations

      The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.

      The below information is taken directly from the publicly available website ClinicalTrials.gov within a week of any updates, and has not been edited.

      Results Disclaimer

      Trial Summary

      This study was designed to evaluate the safety and efficacy of neoadjuvant and adjuvant atezolizumab in participants with resectable Non-Small Cell Lung Cancer (NSCLC). Neoadjuvant therapy consisted of two 21-day cycles with atezolizumab. Following surgery, adjuvant therapy consisted of up to 12 months of atezolizumab in participants who demonstrate clinical benefit with neoadjuvant therapy. All participants who undergo surgery entered a surveillance period, which consisted of standardized blood sample collection and Chest CT Scans, for up to 2 years. All participants were monitored for disease recurrence and survival for up to 3 years after last dose of study drug.

      Genentech, Inc. Sponsor
      Phase 2 Phase
      NCT02927301 , ML39236 Trial Identifier
      Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody Treatments
      Non-Small Cell Lung Cancer Condition
      Official Title

      A Phase II, Open-Label, Multicenter, Single-Arm Study to Investigate the Efficacy and Safety of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients With Stage IB, II, IIIA, or Selected IIIB Resectable and Untreated Non-Small Cell Lung Cancer

      Eligibility Criteria

      All Gender
      ≥ 18 Years Age
      No Healthy Volunteers
      Inclusion Criteria
      • Pathologically documented Stage IB, II, IIIA, or selected IIIB, including T3N2 or T4 (by size criteria, not by mediastinal invasion) NSCLC
      • Adequate pulmonary and cardiac function
      • Available biopsy of primary tumor with adequate samples
      • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
      Exclusion Criteria
      • NSCLC that is clinically T4 by virtue of mediastinal organ invasion or Stage IIIB by virtue of N3 disease
      • Any prior therapy for lung cancer within 3 years.
      • Prior treatment with anti-PD-1 or PD-L1 therapies
      • History or risk of autoimmune disease

      About Clinical Research

      What is a clinical trial? Why should I consider taking part in a clinical trial? And why does Genentech conduct clinical trials?

      Find out now